The trial team in Bangkok, Thailand’s capital announced on 24 September that rates of HIV infection were 31 percent lower in trial participants who got the vaccine than in those who received a placebo. "These new findings represent an important step forward in HIV vaccine research," said Dr Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID), the main funder of the trial. The study, known as RV144, began enrolling 16,000 HIV-negative men and (…)